Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, indicating progress in their drug development pipeline [1] Group 1: Clinical Trial Approval - Jiangsu Heng Rui Medicine Co., Ltd. and its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Heng Rui Medicine Co., Ltd. have been granted the Clinical Trial Approval Notice for HRS-4357 injection and HRS-5041 tablets [1] - The approval is based on the review under the Drug Administration Law of the People's Republic of China, confirming that the drugs meet the registration requirements [1] - The clinical trials will focus on the safety, tolerability, and preliminary efficacy of HRS-4357 in combination with HRS-5041 for the treatment of PSMA-positive prostate cancer, conducted as an open-label, multi-center, phase Ib/II study [1]